ASN's Mission

To create a world without kidney diseases, the ASN Alliance for Kidney Health elevates care by educating and informing, driving breakthroughs and innovation, and advocating for policies that create transformative changes in kidney medicine throughout the world.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005


The Latest on Twitter

Kidney Week

Abstract: SA-OR080

Febuxostat for Patients with CKD Stage G3 with Asymptomatic Hyperuricemia: A Randomized Trial

Session Information

Category: CKD (Non-Dialysis)

  • 1902 CKD (Non-Dialysis): Clinical, Outcomes, and Trials


  • Shibagaki, Yugo, St. Marianna University, Kawasaki, TOKYO, Japan
  • Ohno, Iwao, The Jikei University School of Medicine, Tokyo, Japan
  • Imai, Naohiko, St. Marianna University, Kawasaki, TOKYO, Japan
  • Uchida, Shunya, Teikyo University School of Medicine , Tokyo, ToKyo, Japan
  • Maruyama, Shoichi, Nagoya University Graduate School of Medicine, Nagoya, Japan
  • Ito, Sadayoshi, Tohoku Graduate School of Medicine, Sendai Miyagi, Japan
  • Makino, Hirofumi, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, OKAYAMA, Japan
  • Ohashi, Yasuo, University of Tokyo, Tokyo, Japan
  • Hosoya, Tatsuo, The Jikei University School of Medicine, Tokyo, Japan
  • Kimura, Kenjiro, Tokyo Takanawa Hospital, Tokyo, Japan

Group or Team Name

  • FEATHER Study Investigators

Epidemiological and clinical studies have suggested that urate-lowering therapy may slow the progression of chronic kidney disease (CKD). However, clinical evidence is still scarce.


We conducted a randomized, double-blind, placebo-controlled trial in patients with CKD stage G3 [estimated glomerular filtration rate (eGFR) < 60 and ≧ 30 ml/min/1.73m2] with asymptomatic hyperuricemia (n = 467) at 55 sites in Japan. Participants were randomly assigned, in a 1:1 ratio, to receive febuxostat (loading daily dose: 10 mg on days 1 to 28; maintenance daily dose: 40 mg at weeks 8 to 108) or placebo. The primary endpoint was the slope (mL/min/1.73 m2 per year) of the eGFR. The mean eGFR slope, time-course changes in eGFR, and serum uric acid from baseline through week 108 were measured.


Among 443 patients who underwent randomization, 220 received febuxostat and 222 received placebo. No significant difference was found in the mean eGFR slope between febuxostat (0.23 ± 5.26) and placebo (-0.47 ± 4.48) (difference, 0.70 mL/min/1.73 m2 per year; 95% confidence interval, -0.21 to 1.62) (Figure). A subgroup analysis revealed a significant between-group difference in the kidney function decline-suppressing effect in patients who were negative for proteinuria (difference, 1.79; 95% confidence interval, 0.55 to 3.03) and whose serum creatinine concentration was lower than the median (difference, 1.76; 95% confidence interval, 0.44 to 3.07). The incidence of gouty arthritis was significantly lower (P = 0.007) in the febuxostat group [0.91% (2/219)] than in the placebo group [5.86% (13/222)]. Adverse events specific to febuxostat did not occur.


Febuxostat failed to show a statistically significant renoprotective effect as compared with placebo in Japanese patients with CKD stage G3 with asymptomatic hyperuricemia.


  • Commercial Support